Is Hexagon Nutrition IPO Good or Bad – Detailed Review

Hexagon Nutrition Limited’s IPO is set to open its initial public offering from June 05, 2026, to June 09, 2026. When considering applying for this IPO, potential investors might have questions about whether the Hexagon Nutrition IPO is a good investment and if it's worth subscribing to.

This article provides a comprehensive analysis of Hexagon Nutrition's IPO, covering its business operations and a fundamental analysis of its RHP to help you make an informed investment decision.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

Hexagon Nutrition IPO Review

Hexagon Nutrition Limited IPO is open for subscription from June 05, 2026, to June 09, 2026, with listing expected on June 12, 2026, on NSE and BSE.

The company operates as a pure-play, research-oriented nutrition company. It researches, formulates, and manufactures a wide range of products that address dietary and therapeutic needs, including food fortification, clinical nutrition, and child malnutrition alleviation.

Rather than relying on outsourced formulas, the company utilizes advanced in-house research and development laboratories to formulate and manufacture custom micronutrient blends and specialized, condition-specific consumer foods.

As of the nine months ended December 31, 2025, the company reported revenue from operations of Rs 267.59 Crore, driven by its three-step operational cycle of research and product development, automated and certified cleanroom manufacturing, and global export distribution.

Hexagon Nutrition commands a strong presence in the segment, utilizing three domestic manufacturing facilities located in Nasik (Maharashtra), Chennai (Tamil Nadu), and Thoothukudi (Tamil Nadu), along with one international facility in Tashkent (Uzbekistan).

The company handles the entire life cycle of nutrition development, from raw material sourcing and in-house laboratory testing to blending, automated packaging, and just-in-time global delivery.

Led by Chairman Arun Purushottam Kelkar, Managing Director Vikram Arun Kelkar, Joint Managing Director Nikhil Arun Kelkar, and CFO Soman Nemai Jana, the leadership team leverages extensive expertise in food science, biochemistry, international trade, and financial management.

The company operates within the Indian nutrition and wellness industry. Driven by rising health awareness, the increasing incidence of lifestyle-related chronic illnesses, and governmental food fortification mandates, the total Indian nutrition market is projected to reach Rs 2,81,400 crore by CY30.

Hexagon Nutrition is strategically positioned to capitalize on public health programs, NGOs, and global healthcare organizations transitioning toward highly targeted, nutrient-dense clinical and supplementary food products.

The company’s operations are supported by a wide retail and hospital distribution network in India, reaching over 20,843 healthcare professionals through an omnichannel model, alongside exporting products to over 75 countries.

Financially, Hexagon Nutrition shows steady operational revenues and consistent cash generation, with strong profitability in recent periods.

Its revenue from operations grew from Rs 278.50 Crore in FY23 to Rs 324.93 Crore in FY25. For the nine months ended December 31, 2025, it reported a Profit After Tax (PAT) of Rs 27.03 Crore, continuing its track record of strong profitability following a net profit of Rs 24.38 Crore in FY25.

The company maintains healthy operational metrics, with an EBITDA margin of 14.03% and a Return on Equity (RoE) of 13.02% as of December 31, 2025.

Key strengths include its integrated value chain, established consumer brands, a diversified global footprint across 75+ countries, long-term customer relationships, and advanced, certified manufacturing setups.

Primary risks include a dependence on its premix formulation segment, a concentration of revenue from key customers, raw material sourcing risk due to the absence of long-term contracts, potential production disruptions at the Nashik facility during its proposed reconstruction, and high employee attrition rates.

The book-built issue consists entirely of an Offer for Sale (OFS) of up to 30,859,704 Equity Shares, which will be received by the Selling Shareholders.

Shares are priced in the hexagon nutrition ipo price band of Rs 42 to Rs 45 per share, with a minimum lot size of 333 shares.

What does Hexagon Nutrition do?

Hexagon Nutrition Limited operates as a differentiated and research-oriented pure-play nutrition company. It manufactures a wide range of products that address food fortification, clinical nutrition, and child malnutrition.

Rather than relying on external sourcing for its formulations, the company utilizes advanced in-house research and development laboratories to formulate and manufacture custom micronutrient blends and specialized, condition-specific foods.

This operational cycle is carried out in three main steps:

Step 1: Research, product formulation, and testing at dedicated in-house R&D centers in Nashik and Chennai.

Step 2: Automated manufacturing in certified cleanroom facilities to ensure strict quality control and safety.

Step 3: Direct distribution and marketing of branded wellness lines alongside export delivery of therapeutic and premix products.

Hexagon Nutrition Limited, through its manufacturing facilities, commands a strong presence in the segment, with plants located in Nashik (Maharashtra), Chennai (Tamil Nadu), Thoothukudi (Tamil Nadu), and Tashkent (Uzbekistan).

The company handles the entire life cycle of nutrition development, from raw material sourcing and in-house laboratory testing to blending, automated packaging, and just-in-time global delivery. They leverage multi-stage inspection, testing, and validation procedures to maintain food safety and quality.

Hexagon Nutrition Business Segments

The company serves its retail and institutional clients through three main business segments:

• Premix Formulations Segment (51.47% of Operations Revenue): This is the company's primary business area for the nine months ended December 31, 2025. It involves manufacturing custom vitamin and mineral premixes supplied to leading food, beverage, and dairy FMCG brands for food fortification.

• Branded & Clinical Nutrition Segment (30.34% of Operations Revenue): This segment involves manufacturing and selling disease-specific and daily wellness nutrition products under brands like PENTASURE (adult wellness), OBESIGO (weight management), PEDIAGOLD (pediatric care), and NUTRONE (preventive wellness) for the nine months ended December 31, 2025.

• Therapeutic Nutrition Segment (17.93% of Operations Revenue): This segment focuses on therapeutic nutrition solutions (RUFs & MNPs) designed to treat severe and moderate acute malnutrition among vulnerable children and pregnant/lactating women in collaboration with global NGOs and healthcare organizations for the nine months ended December 31, 2025.

Key Operational Features

The company’s operations are supported by a network of four manufacturing facilities. They hold globally recognized quality certifications alongside being GAIN-approved for public health programs.

Chairman Arun Purushottam Kelkar, Managing Director Vikram Arun Kelkar, Joint Managing Director Nikhil Arun Kelkar, and CFO Soman Nemai Jana lead the company, leveraging their extensive expertise in food science, supply chain logistics, and financial management.

What is the market opportunity for Hexagon Nutrition?

Hexagon Nutrition Limited operates within the Indian nutrition, wellness, and food fortification industry. The sector is undergoing steady growth, driven by rising health awareness, the increasing incidence of lifestyle-related chronic illnesses, and governmental food fortification mandates.

The total Indian nutrition market is projected to reach Rs 2,81,400 crore by CY30. Driven by public health programs, NGOs, and global healthcare organisations transitioning toward highly targeted, nutrient-dense clinical and supplementary foods, the market is expanding rapidly. This expansion is supported by growing public and institutional interest in food fortification, such as wheat, rice, milk, and salt, to combat micronutrient deficiencies.

Crucially, the clinical and therapeutic nutrition segment remains high-growth as consumers and healthcare providers increasingly focus on preventive healthcare and clinical nutrition support during illness recovery.

Despite this potential, the industry faces persistent challenges, including strict regulatory frameworks, fluctuations in global raw material prices, high R&D costs for product development, and localized logistics and infrastructure constraints.

Industry statistics are sourced from the Hexagon Nutrition Limited Red Herring Prospectus (RHP) dated May 25, 2026.

Is Hexagon Nutrition Limited Profitable?

Note: Ratios for the period ended Dec 31, 2025, are non-annualised.

• Revenue from Operations: This is the total money the company earned from its core business activities, including selling premixes, branded clinical nutrition, and therapeutic foods. It shows the overall scale of the core business, which grew from Rs 278.50 Crore in FY23 to Rs 324.93 Crore in FY25.

• EBITDA Margin: This is the core operating profit shown as a percentage of revenue from operations. It tells you how efficient the company is at turning sales into operating profit. It rose from 6.17% in FY23 to 14.03% in 9M FY26, showing that the company's operations became more profitable over time.

• Profit After Tax (PAT): This is the actual bottom-line net profit left for the owners after paying every single expense, interest, and tax. The company is consistently profitable, with its PAT growing from Rs 5.82 Crore in FY23 to Rs 24.38 Crore in FY25, and recording Rs 27.03 Crore in the nine months ended Dec 31, 2025.

• Return on Equity (RoE): This measures how much profit the company generates for every rupee of shareholder equity invested. A higher percentage means better capital efficiency. It grew steadily to hit a strong 10.47% in FY25 and 13.02% in the nine months ended Dec 31, 2025.

• Debt to Equity: This ratio compares the company’s total debt to the money invested by shareholders. It shows the company's financial leverage. It declined from 0.32 in FY23 to 0.14 in FY25 due to debt repayment and stood at 0.18 in 9M FY26, indicating a highly conservative and comfortable leverage profile.

Financial figures are sourced from the Hexagon Nutrition Limited Red Herring Prospectus (RHP) dated May 25, 2026.

Strengths and Risks of Hexagon Nutrition IPO

Let's examine the strengths and weaknesses to determine whether the Hexagon Nutrition IPO is good or bad for investors.

Strengths

• Integrated value chain: Handling the complete value chain in-house, from R&D to automated manufacturing, ensures end-to-end quality and compliance control.

• Established consumer brands: High-margin brands like PENTASURE, OBESIGO, PEDIAGOLD, and NUTRONE are well-received in the clinical and wellness markets.

• Diversified global footprint: Exporting products to over 75 countries reduces localized market risk and positions the company as a key global player.

• Long-term customer relationships: Building multi-year relationships with multinational food and beverage brands and global NGOs ensures high repeat business.

• Advanced manufacturing setups: Utilizing four certified, state-of-the-art facilities with FSSC 22000 and GAIN approvals supports regulatory and bulk order readiness.

Risks

• Dependence on premix segment: Relying heavily on the custom premix formulation segment, which contributed 51.47% of revenue in the nine months ended December 31, 2025.

• Absence of long-term contracts: Procuring key raw materials like vitamins at spot prices without long-term agreements exposes the company to price volatility.

• Reconstruction of Nashik Facility: Planned modifications at its Nashik plant to resolve agricultural land-use compliance may cause short-term production disruptions.

• Customer concentration: A significant portion of revenue is concentrated among a few top institutional and NGO customers.

• High employee attrition: The company experiences high attrition rates, with the consolidated weighted attrition being 23.48% in 9M FY26 and 34.48% in FY25.

Strategies of Hexagon Nutrition IPO

• Expanding therapeutic nutrition products: The company is expanding its portfolio of disease-specific nutrition products, including diabetes, renal, hepatic, and bariatric nutrition solutions, to cater to the growing demand for specialised healthcare nutrition.

• Growing consumer nutrition brands: Hexagon Nutrition is strengthening brands such as Pentasure, Obesigo, and Pediagold to capture rising consumer demand for wellness, preventive healthcare, and nutritional supplementation products.

• Strengthening premix leadership: As one of India's largest micronutrient premix manufacturers, the company aims to expand its customised nutrition solutions business across food, beverage, dairy, pharmaceutical, and FMCG industries.

• Expanding global presence: With operations spanning more than 70 countries, the company plans to deepen its international footprint by leveraging its distribution network, subsidiaries, and long-standing customer relationships.

• Enhancing research and innovation: The company continues to invest in its two dedicated R&D centres to develop science-backed formulations, customised nutrition solutions, and new product offerings across nutrition categories.

• Leveraging food fortification opportunities: Hexagon Nutrition is increasing its focus on public health nutrition and food fortification programmes, building on its position as one of the largest licensed suppliers of Micronutrient Powders (MNPs) under UN-supported initiatives.

Hexagon Nutrition IPO vs. Peers

The following securities are mentioned as examples for comparative purposes only and do not constitute a recommendation to buy or sell.

Hexagon Nutrition Limited demonstrates healthy financial efficiency and operational performance that compares favourably with its listed industry peers, including Zydus Wellness and Nestle India.

• Revenue from Operations: Shows the overall market footprint. While Nestle India (Rs 20,201.56 Crore) and Zydus Wellness (Rs 2,708.90 Crore) operate at a much larger scale, Hexagon Nutrition (Rs 324.93 Crore) is growing rapidly and represents a highly specialized, pure-play nutrition competitor.

• EBITDA Margin: Measures core operational profitability. Nestle leads the group at 24.42%, followed by Zydus Wellness at 14.02%. Hexagon Nutrition has improved its operational efficiency significantly, reaching an EBITDA margin of 12.33% in FY25 and 14.03% in the nine months ended Dec 31, 2025.

• Debt to Equity: Measures financial leverage. Hexagon Nutrition maintains a highly conservative and comfortable balance sheet with a debt-to-equity ratio of 0.14, which is comparable to Zydus Wellness (0.03) and lower than Nestle India (0.30).

• Return on Equity (RoE): Measures capital efficiency. Nestle leads with an exceptional RoE of 87.30%. Hexagon Nutrition outperforms Zydus Wellness with an RoE of 10.47% in FY25, compared to Zydus' return of 6.10%.

Objectives of Hexagon Nutrition IPO

The offering consists entirely of an Offer for Sale (OFS) of up to 3,08,59,704 Equity Shares, meaning all proceeds will be received by the selling shareholders.

The company will not receive any proceeds from this public offering. The primary objective of the listing is to establish a public market for the Equity Shares and provide liquidity to the existing investors.

Hexagon Nutrition IPO Details

IPO Dates

Hexagon Nutrition IPO will be open for subscription from June 05, 2026, to June 09, 2026. The allotment of shares to investors will take place on June 10, 2026, and the company is expected to be listed on the NSE and BSE on June 12, 2026.

IPO Issue Price

Hexagon Nutrition is offering its shares in the price band of Rs 42 to Rs 45 per share. This means you would require an investment of Rs 14,985 per lot (333 shares) if you are bidding for the IPO at the upper price band.

IPO Size

Hexagon Nutrition is launching a Rs 139 crore IPO, consisting entirely of an offer for sale of about 3.09 crore shares.

IPO Allotment Status

Investors who applied for the IPO can check their IPO allotment status on June 10, 2026, through the registrar's website, Kfin Technologies Limited, BSE, NSE, or through their stockbroker platform.

IPO Listing Date

The shares of Hexagon Nutrition are expected to be listed on the NSE and BSE on June 12, 2026.

IPO Application Link

Open demat account with Rupeezy today and enjoy a seamless experience when applying for the IPO. With an easy-to-use platform, Rupeezy makes the IPO application process quick and hassle-free.

Apply for Hexagon Nutrition IPO